Channel Therapeutics Corporation
CHRO · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2,579 | $392 | $209 |
| Gross Profit | $0 | -$2,579 | -$392 | -$209 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,179 | $2,579 | $392 | $209 |
| G&A Expenses | $6,392 | $4,283 | $1,926 | $630 |
| SG&A Expenses | $6,392 | $4,283 | $1,926 | $630 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7,571 | $6,862 | $2,318 | $839 |
| Operating Income | -$7,571 | -$6,862 | -$2,318 | -$839 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$384 | -$519 | -$140 | $244 |
| Pre-Tax Income | -$7,955 | -$7,381 | -$2,459 | -$595 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,955 | -$7,381 | -$2,459 | -$595 |
| % Margin | – | – | – | – |
| EPS | -1.43 | -1.28 | -0.43 | -0.1 |
| % Growth | -11.7% | -197.7% | -330% | – |
| EPS Diluted | -1.43 | -1.28 | -0.43 | -0.1 |
| Weighted Avg Shares Out | 5,574 | 5,768 | 5,768 | 5,768 |
| Weighted Avg Shares Out Dil | 5,574 | 5,768 | 5,768 | 5,768 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$786 | $519 | $140 | $0 |
| Depreciation & Amortization | $1,170 | $0 | $690 | $839 |
| EBITDA | -$7,571 | -$6,862 | -$1,628 | $0 |
| % Margin | – | – | – | – |